Key Takeaways
- •Mass is a sum, and sums are degenerate. Any rearrangement of the same residues has the same mass. For TB-500 that is 1,260 sequences a mass alone cannot separate.
- •Leucine and isoleucine are the same mass. They are structural isomers at 113 Da, so no single-stage tandem experiment distinguishes them. TB-500 begins with a leucine.
- •Lysine and glutamine differ by about 0.036 Da. On an instrument without the resolving power to see that gap, they are interchangeable. TB-500 contains two lysines and a glutamine.
- •Edman degradation cannot start on a blocked N-terminus. TB-500 is acetylated and melanotan II is both acetylated and cyclic, so the classic sequencing method is unavailable on exactly the compounds that most need it.
- •HPLC establishes homogeneity, not identity. A single sharp peak says one substance dominates. It does not say which substance.
- •The practical answer is co-elution against a reference standard, and almost nobody in this market publishes one.
TB-500 is the heptapeptide Ac-LKKTETQ: the N-acetylated fragment spanning residues 17 to 23 of thymosin beta-4. Seven residues, one of them repeated twice, another repeated twice again.
Take those same seven residues and put them in a different order. There are 1,260 distinct arrangements, and every single one weighs exactly the same. A mass spectrometer reports the mass. It cannot, from that number, tell you which of the 1,260 you have.
That is the identity problem in one example, and it is the question almost no certificate in this market actually answers. Purity is reported constantly. Content is reported occasionally. Identity, meaning is the substance in this vial the sequence printed on the label, is usually inferred from a single mass and presented as settled.
This article covers what each analytical method can and cannot establish about identity, why the peptides sold in this market are unusually hard cases, and what a certificate would have to contain before the identity question is genuinely closed. Volta sells TB-500 and melanotan II, both of which appear below as difficult examples. All material is supplied for laboratory research use only.
The three questions a certificate can answer
They are separate, they use different instruments, and a strong answer to one implies nothing about the others.
| Question | Plain form | Method | What a pass actually means |
|---|---|---|---|
| Purity | How much of what is detectable is the main component? | RP-HPLC, area percent at a stated wavelength | One component dominates the chromatogram |
| Content | How much target peptide is in the vial? | Mass balance: assay against a standard, water, counterion, residual solvents | The label's milligram figure is or is not honest |
| Identity | Is the main component the sequence on the label? | MS for mass, MS/MS or Edman for order, co-elution against a reference standard | The substance is the one named |
Most certificates answer the first, gesture at the second, and treat the third as a corollary of a matching molecular weight. It is not a corollary. It is a separate experiment.
Why mass is not identity
A peptide's monoisotopic mass is the sum of its residue masses plus water. Addition is commutative, so order contributes nothing to the total. This is not a subtle instrument limitation, it is arithmetic.
Work it through on TB-500. The sequence is Leu-Lys-Lys-Thr-Glu-Thr-Gln, acetylated at the N-terminus. Seven positions, with lysine appearing twice and threonine twice, gives 7! / (2! x 2!) = 1,260 distinct sequences, all built from the same residues, all identical in mass, all producing the same number on a mass spectrometer.
Then two further degeneracies stack on top:
Leucine and isoleucine are isomers. Both are 113 Da as residues, differing only in where a methyl branch sits. A standard single-stage tandem experiment cannot separate them at all; distinguishing them requires specialised approaches such as MS3 workflows or charge-transfer dissociation, which are not routine and are essentially never on a peptide vendor's certificate. TB-500 starts with a leucine, so Ac-IKKTETQ is invisible to the usual test.
Lysine and glutamine are isobaric. Their residue masses are 128.09496 and 128.05858, a gap of about 0.036 Da. High-resolution instruments resolve it comfortably. Lower-resolution instruments do not, and a certificate reporting a mass to one decimal place has thrown the distinguishing information away before you ever see it. TB-500 contains two lysines and one glutamine.
None of this means suppliers are routinely shipping scrambled peptides. It means that if one did, the standard certificate would not reveal it. The check most buyers rely on is not sensitive to the failure mode they are worried about.
Why the hard cases are exactly the popular compounds
The classical way to read a sequence directly is Edman degradation, which clips residues off the N-terminus one at a time and identifies each. It works well for roughly 20 to 30 residues and degrades beyond about 40.
It also has an absolute prerequisite: a free N-terminal amino group. If the N-terminus is acetylated, or has cyclised to pyroglutamate, or is otherwise blocked, the chemistry has nothing to attack and the sequencing run yields nothing at all.
Now look at what this market sells.
| Compound | Structural feature | Consequence for identity testing |
|---|---|---|
| TB-500 (Ac-LKKTETQ) | N-terminally acetylated | Edman cannot start. Identity rests on MS/MS or a reference standard |
| Melanotan II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) | Acetylated, C-terminally amidated and a cyclic lactam | Edman cannot start; cyclisation also complicates fragmentation, since a ring has no free ends to unzip from |
| CJC-1295 | Non-standard residues including D-amino acid substitution | A D-residue has the identical mass to its L-form. Mass cannot detect the wrong stereochemistry |
| Semax, Selank | Short, with modified termini | Few residues means few fragments and less to constrain an assignment |
The D-amino acid case is the sharpest of them. A D-residue and an L-residue are mirror images with identical molecular formulae and identical masses. A synthesis that racemised at a position, or simply used the wrong building block, produces material that a mass spectrometer certifies as correct and that may be biologically inert. Chirality is invisible to mass. It takes chiral chromatography, or amino acid analysis after chiral derivatisation, to see it, and neither appears on retail certificates.
In Stock and Shipping from British Columbia
Every vial below ships domestically within Canada with a batch-specific Certificate of Analysis. Supplied for laboratory research use only.
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
KLOW 80mg
80mg
KPV 10mg
10mg
Ipamorelin 5mg
5mg
MOTS-C 10mg
10mg
TB-500 10mg
10mg
GHK-Cu 100mg
100mg
SS-31 10mg
10mg
5-Amino-1MQ 10mg
10mg
>99% HPLC purity standard. Read the Certificates of Analysis.
See the full Canadian catalogueWhat each method actually establishes
| Method | Establishes | Does not establish |
|---|---|---|
| RP-HPLC, area percent | One component dominates the detectable material | Which component. Anything the detector cannot see at that wavelength |
| Single-stage MS | The intact mass | Order, chirality, isomers, or anything else degenerate with mass |
| MS/MS fragmentation | A fragment ladder constraining the order, often strongly | Leu vs Ile in a single stage. Chirality. Ring positions in cyclic peptides |
| Edman degradation | Order, read directly, residue by residue | Anything with a blocked or absent N-terminus. Long sequences |
| Amino acid analysis | Composition and, with a standard, quantity | Order. Tryptophan is destroyed by standard acid hydrolysis and is reported separately or not at all |
| Co-elution with a reference standard | That the material behaves identically to a known-correct sample under the same conditions | Nothing, if no reference standard exists for the compound |
The last row is the practical answer, and also the one this market cannot generally deliver. Co-elution is the routine identity test in pharmaceutical analysis: run the sample, run a characterised reference standard, run them together, and show a single peak. It is cheap and decisive. It requires a reference standard, and for most research peptides no certified reference standard exists to buy.
That absence is a real limitation of research-grade material generally, ours included, and it is worth stating plainly rather than papering over: for most of these compounds, nobody, at any price, can hand you a certified identity in the way a pharmacopoeial monograph would define it.
What to actually look for
Given that the perfect answer is unavailable, the useful question is which certificates carry more identity information than others. In descending order of value:
1. MS/MS with a reported fragment series, not just an intact mass. A b/y ion ladder constrains the order across most of the sequence. It is meaningfully harder to fake than a single number and it is the strongest thing routinely available.
2. The mass reported to enough decimal places to matter. A monoisotopic mass to four decimals on a high-resolution instrument carries real information. A nominal mass to one decimal has already discarded the lysine and glutamine distinction.
3. The instrument and method named. "MS confirmed" is not a method. An instrument type, an ionisation mode and a mass accuracy figure are.
4. Purity and identity on the same document for the same lot. Two reports from two batches, stapled together, establish nothing about the vial you receive.
5. An explicit statement of what was not tested. A certificate that says chirality was not assessed is more trustworthy than one that quietly implies everything was.
The mass spec tool checks whether a reported mass is consistent with a claimed sequence, the molecular weight calculator computes the expected value, and the COA explainer walks a certificate field by field. For the documents rather than the chemistry, how to tell if a peptide supplier is legitimate covers traceability, and the counterfeit detection guide covers the rest.
The honest summary
A matching molecular weight is a necessary condition for correct identity and a weak sufficient one. It rules out gross errors: the wrong compound entirely, a truncated synthesis, a missing modification. It does not rule out a rearrangement, an isomer, a stereochemical error, or a substitution between residues too close in mass for the instrument used.
For most laboratory work that residual uncertainty is tolerable, because most experiments will fail loudly if the material is wrong. It stops being tolerable when a result is going to be published, compared against literature values, or built on. At that point the material's identity is part of the result, and "the certificate said the mass matched" is a thinner foundation than it looks.
Volta reports HPLC purity and mass-spectrometry identity per lot, and does not currently publish fragment-ion data or chiral analysis. Both of those are gaps rather than achievements, and naming them is more useful to a researcher than a badge would be.
Frequently Asked Questions
Does a matching molecular weight prove a peptide is correct?
No. It proves the total mass is consistent with the claimed composition. Because mass is a sum, every rearrangement of the same residues gives the same total, as do isomeric substitutions such as leucine for isoleucine and stereochemical errors such as a D-residue for an L-residue. A matching mass rules out large errors and is not a proof of sequence.
Why can't mass spectrometry tell leucine from isoleucine?
They are structural isomers: identical atoms, identical formula, identical mass, differing only in the position of a methyl branch. Standard tandem experiments separate residues by mass difference, and here there is none. Specialised methods exist, including MS3 approaches and charge-transfer dissociation, but they are research techniques rather than routine quality control.
Why is Edman degradation not used on research peptides?
Often it cannot be. Edman chemistry requires a free N-terminal amino group, and many of the most-sold compounds are N-terminally acetylated or cyclic, which blocks the reaction outright. TB-500 and melanotan II are both in that category. Where the N-terminus is free, Edman remains an excellent direct read of sequence.
What is co-elution and why does it matter?
You run your sample, run a characterised reference standard of the same compound, then run a mixture of the two. If the mixture gives one peak rather than two, the sample behaves identically to the standard under those conditions, which is strong evidence of identity. It is the standard pharmaceutical approach, and it is largely unavailable here because certified reference standards do not exist for most research peptides.
Is a peptide with the right mass but the wrong sequence likely in practice?
Deliberate substitution of that kind is unlikely, because it is harder to produce than simply supplying the correct compound. The realistic risks are accidental: incomplete coupling leaving deletion sequences, racemisation at a residue during synthesis, or a mislabelled vial. All three can produce material whose reported mass looks acceptable, which is exactly why identity deserves its own evidence rather than being inferred.
Does a higher purity number make identity more certain?
No, and conflating the two is the most common error here. Purity is a ratio describing how much of the detectable material is the main peak. If the main peak is the wrong substance, a 99.9% result describes a very pure sample of the wrong thing. Purity and identity are independent, and a certificate needs to answer both.
